We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals

285 hedge funds and large institutions have $6.42B invested in Rhythm Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 101 increasing their positions, 89 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

776% more call options, than puts

Call options by funds: $16.4M | Put options by funds: $1.87M

25% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 51

13% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 89

2% more funds holding

Funds holding: 279285 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

1.43% less ownership

Funds ownership: 109.17%107.74% (-1.4%)

18% less capital invested

Capital invested by funds: $7.8B → $6.42B (-$1.38B)

Holders
285
Holders Change
+6
Holders Change %
+2.15%
% of All Funds
3.51%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
64
Increased
101
Reduced
89
Closed
51
Calls
$16.4M
Puts
$1.87M
Net Calls
+$14.5M
Net Calls Change
+$1.06M
Name Holding Trade Value Shares
Change
Change in
Stake
CUAMC
151
China Universal Asset Management Company
China
$1.05M +$121K +1,243 +11%
DnB Asset Management
152
DnB Asset Management
Norway
$974K +$3.11K +32 +0.3%
ProShare Advisors
153
ProShare Advisors
Maryland
$932K -$185K -1,902 -15%
Barclays
154
Barclays
United Kingdom
$926K -$11.7M -120,784 -92%
ET
155
Entropy Technologies
New York
$897K +$761K +7,826 +314%
CFS
156
Cannon Financial Strategists
Georgia
$870K
TFA
157
Toth Financial Advisory
Virginia
$870K
Marshall Wace
158
Marshall Wace
United Kingdom
$837K +$936K +9,628 New
AA
159
AlphaCentric Advisors
Puerto Rico
$809K +$413K +4,245 +84%
Los Angeles Capital Management
160
Los Angeles Capital Management
California
$802K -$1.47M -15,115 -62%
Hudson Bay Capital Management
161
Hudson Bay Capital Management
Connecticut
$793K +$887K +9,120 New
HighTower Advisors
162
HighTower Advisors
Illinois
$788K +$881K +9,058 New
CP
163
CenterBook Partners
Connecticut
$785K +$878K +9,026 New
ETC
164
Exchange Traded Concepts
Oklahoma
$736K +$232K +2,383 +39%
PCM
165
Prelude Capital Management
New York
$728K +$814K +8,372 New
TRCT
166
Tower Research Capital (TRC)
New York
$671K +$462K +4,753 +160%
VIA
167
Virtus Investment Advisers
Connecticut
$647K +$138K +1,417 +24%
Teacher Retirement System of Texas
168
Teacher Retirement System of Texas
Texas
$637K -$100K -1,029 -12%
PNC Financial Services Group
169
PNC Financial Services Group
Pennsylvania
$603K +$222K +2,279 +49%
IMC Chicago
170
IMC Chicago
Illinois
$582K +$651K +6,697 New
EFM
171
E Fund Management
China
$561K +$628K +6,453 New
LPL Financial
172
LPL Financial
California
$539K +$75K +771 +14%
TTSTC
173
Texas Treasury Safekeeping Trust Company
Texas
$535K +$598K +6,154 New
CCIA
174
Campbell & Co Investment Adviser
Maryland
$518K +$579K +5,958 New
Canada Life
175
Canada Life
Manitoba, Canada
$507K

RYTM Hedge Fund Activity: Q1 2026 in Review

285 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2026, worth a combined $6.42B — down 18% from $7.8B a quarter earlier.

Buyers outnumbered sellers: 64 funds opened new RYTM positions and 51 closed out — a net gain of 13 holders — while 101 added to existing stakes and 89 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $123M. The largest seller was NEA Management Company, exiting entirely with an estimated $311M sold.

  • 285 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2026, up from 279 in Q4 2025.
  • Funds reported $6.42B of Rhythm Pharmaceuticals stock for Q1 2026, down 18% quarter-over-quarter.
  • 64 funds opened new Rhythm Pharmaceuticals positions in Q1 2026 and 51 closed out, a net change of +13 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $123M added.
  • The largest Rhythm Pharmaceuticals seller in Q1 2026 was NEA Management Company, an estimated $311M sold.

Based on aggregated 13F filings for Q1 2026.